Tacrolimus Concentration Is Effectively Predicted Using Combined Clinical and Genetic Factors in the Perioperative Period of Kidney Transplantation and Associated with Acute Rejection

Figure 2

Effect of the CYP3A5 genotype on tacrolimus PK variability.

(a) Tacrolimus concentration/dose ratio over time, stratified by CYP3A5 genotype: CYP3A5 expresser (AA+AG, 1/1 + 1/3) and nonexpresser (GG, 3/3) groups

(b) Tacrolimus concentration over time, stratified by CYP3A5 genotype: CYP3A5 expresser (AA+AG, 1/1 + 1/3) and nonexpresser (GG, 3/3) groups